The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including
hyperlipidemia,
weight gain,
obesity,
insulin resistance, hypertension, atherosclerosis,
fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal
brake response to surgical intervention e.g. Roux-en-Y
gastric bypass (RYGB)) as both activate the ileal
brake, which acts in the
gastrointestinal tract and the liver of a
mammal to control
metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension,
lipid accumulation, and the like) resulting from progression of
metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of
metabolic syndrome, including Type 2 diabetes and
obesity, with one medicament, which contains glucose as an activation agent for the ileal
brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB
surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome.In other aspects, the invention provides ileal brake
hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in
selective control of
appetite, stabilizing blood glucose and
insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB
surgery, but having at least 20% of the
potency to stimulate the hormonal response of the ileal brake of humans.